4.7 Review

Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide

期刊

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 38, 期 8, 页码 864-886

出版社

WILEY
DOI: 10.1111/apt.12460

关键词

-

资金

  1. Danone
  2. Almirall
  3. Shire
  4. AstraZeneca
  5. Canadian Association for Gastroenterology
  6. Metagenics
  7. Yakult
  8. BioProx
  9. Danisco
  10. Kemin
  11. Lesaffre
  12. Roquette
  13. Vesale Pharma
  14. Norgine
  15. Abbott
  16. GlaxoSmithKline AEBE
  17. Pfizer Hellas A.E./Pfizer Inc.
  18. European Commission
  19. ESPCG
  20. ZON MW, the Dutch Research Institute
  21. Danone (Paris, France)
  22. Medical Research Council [MR/K02325X/1] Funding Source: researchfish

向作者/读者索取更多资源

BackgroundEvidence suggests that the gut microbiota play an important role in gastrointestinal problems. AimTo give clinicians a practical reference guide on the role of specified probiotics in managing particular lower gastrointestinal symptoms/problems by means of a systematic review-based consensus. MethodsSystematic literature searching identified randomised, placebo-controlled trials in adults; evidence for each symptom/problem was graded and statements developed (consensus process; 10-member panel). As results cannot be generalised between different probiotics, individual probiotics were identified for each statement. ResultsThirty seven studies were included; mostly on irritable bowel syndrome [IBS; 19 studies; treatment responder rates: 18-80% (specific probiotics), 5-50% (placebo)] or antibiotic-associated diarrhoea (AAD; 10 studies). Statements with 100% agreement and high' evidence levels indicated that: (i) specific probiotics help reduce overall symptom burden and abdominal pain in some IBS patients; (ii) in patients receiving antibiotics/Helicobacter pylori eradication therapy, specified probiotics are helpful as adjuvants to prevent/reduce the duration/intensity of AAD; (iii) probiotics have favourable safety in patients in primary care. Items with 70-100% agreement and moderate' evidence were: (i) specific probiotics help relieve overall symptom burden in some patients with diarrhoea-predominant IBS, and reduce bloating/distension and improve bowel movement frequency/consistency in some IBS patients and (ii) with some probiotics, improved symptoms have led to improvement in quality of life. ConclusionsSpecified probiotics can provide benefit in IBS and antibiotic-associated diarrhoea; relatively few studies in other indications suggested benefits warranting further research. This study provides practical guidance on which probiotic to select for a specific problem.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据